This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via ISI Web of Science (6) Citing Articles via Google Scholar Google Scholar Articles by Kadish, A. Articles by Levine, J. Search for Related Content PubMed PubMed Citation Articles by Kadish, A. Articles by Levine, J.

Patients With Recently Diagnosed Nonischemic Cardiomyopathy Benefit From Implantable Cardioverter-Defibrillators

Alan Kadish, MD^_*,1,_*, Andi Schaechter, RN^_*, Haris Subacius, MA^_*, Emil Thattassery, MD^_*, William Sanders, MD^,3, Kelley P. Anderson, MD^,5, Alan Dyer, PhD^_*,2, Jeffrey Goldberger, MD^_*,4 and Joseph Levine, MD

^_* Clinical Trials Unit, Bluhm Cardiovascular Institute, Northwestern Memorial Hospital, the Division of Cardiology, Feinberg School of Medicine, Chicago, Illinois
University of North Carolina, Chapel Hill, North Carolina
Marshfield Clinic, Marshfield, Wisconsin
Heart Center, St. Francis Hospital, Roslyn, New York.

View larger version (17K): [in a new window]   Figure 1 Kaplan-Meier estimates of death from any cause by treatment arm in patients with three months of nonischemic dilated cardiomyopathy (NIDCM) duration or less (A) and patients with more than three months of NIDCM duration (B). ICD = implantable cardioverter-defibrillator.

View larger version (17K): [in a new window]   Figure 2 Kaplan-Meier estimates of death from any cause by treatment arm in patients with nine months of nonischemic dilated cardiomyopathy (NIDCM) duration or less (A) and patients with more than nine months of NIDCM duration (B). ICD = implantable cardioverter-defibrillator.